ANI Pharma (ANIP) Reports Q4 EPS of 84c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
ANI Pharmaceuticals Reports Full Year 2016 Results and Fourth Quarter Results and Provides 2017 Guidance
March 2, 2017 8:30 AM ESTBAUDETTE, Minn., March 2, 2017 /PRNewswire/ --
For the full year ended December 31, 2016:
Record net revenues of $128.6 million, an increase of 69% versus the prior year GAAP net income of $3.9 million, including $6.7 million non-cash impairment charge for a non-core asset Diluted GAAP earnings per share of $0.34, including impact of non-cash impairment charge of $0.36, net of tax Adjusted non-GAAP EBITDA of $61.1 million Adjusted non-GAAP net income per diluted share of $3.78 (previous methodology)For the fourth quarter 2016:
Net... More